Exploratory project to compare IO Biotech antigens linked to Mymetics’ virosomes in a preclinical tumor model

Epalinges, Switzerland, May 25, 2020 – Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines, announced today that Mymetics BV, the Dutch subsidiary of Mymetics Corporation, will start a research project with IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology.

Media Name Media Type Description Download
Announcement PDF Download